The management of patients with metastatic prostate cancer during the COVID-19 pandemic
| Autor: | Nathalie Ibrahim, Elie Nemr, Clarisse Kattan, Elie El Rassy, Rita Maria Khoury Abboud, Joseph Kattan, Tarek Assi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Pneumonia Viral coronavirus Comorbidity Antiviral Agents TMPRSS2 Androgen deprivation therapy Betacoronavirus 03 medical and health sciences Prostate cancer 0302 clinical medicine Internal medicine Pandemic medicine Humans 030212 general & internal medicine Pandemics Special Report Immunosuppression Therapy Chemotherapy immunosuppression SARS-CoV-2 business.industry Serine Endopeptidases COVID-19 Cancer Androgen Antagonists Immunosuppression General Medicine prostate cancer medicine.disease hormone sensitive COVID-19 Drug Treatment metastatic Prostatic Neoplasms Castration-Resistant 030220 oncology & carcinogenesis Coronavirus Infections business castrate resistant |
| Zdroj: | Future Oncology |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|